目的 探討甘海胃康膠囊聯(lián)合艾司奧美拉唑治療胃潰瘍的臨床療效。方法 選取2020年11月-2022年11月徐州醫(yī)科大學(xué)附屬連云港醫(yī)院收治的124例胃潰瘍患者，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各62例。對(duì)照組口服艾司奧美拉唑鎂腸溶膠囊，20 mg/次，1次/d。治療組在對(duì)照組治療此基礎(chǔ)上口服甘海胃康膠囊，6粒/次，3次/d。兩組療程均為6周。觀察兩組的臨床療效、幽門(mén)螺桿菌（Hp）根除率及潰瘍愈合率。比較治療前后兩組典型表現(xiàn)評(píng)分、慢性病生命質(zhì)量測(cè)定量表體系之消化潰瘍量表第二版（QLICD-PU V2.0）評(píng)分及血清胃蛋白酶原Ⅰ與胃蛋白酶原Ⅱ比值（PGR）、胃泌素-17（G-17）、白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，治療組總有效率是96.77%，較對(duì)照組的87.10%顯著提高（P<0.05）。治療后，兩組胃脘疼痛、胃脹、反酸、噯氣評(píng)分及其總分均顯著降低（P<0.05）；治療后，治療組典型表現(xiàn)評(píng)分降低更顯著（P<0.05）。治療后，兩組QLICD-PU V2.0中共性模塊、特異性模塊評(píng)分及量表總分均顯著增加（P<0.05）；治療后，治療組QLICD-PU V2.0評(píng)分高于對(duì)照組（P<0.05）。治療組Hp根除率、潰瘍愈合率分別為91.94%、75.81%，均顯著高于對(duì)照組的79.03%、58.06%（P<0.05）。治療后，兩組血清PGR、G-17、IL-6水平均顯著下降（P<0.05）；且治療后，治療組血清PGR、G-17、IL-6水平均顯著低于對(duì)照組（P<0.05）。結(jié)論 甘海胃康膠囊聯(lián)合艾司奧美拉唑治療胃潰瘍療效較好，能有效促進(jìn)患者典型表現(xiàn)的減輕、生命質(zhì)量的提升及Hp根除和潰瘍愈合，對(duì)胃黏膜功能恢復(fù)及炎癥反應(yīng)緩解具有較好的調(diào)控作用，值得臨床推廣應(yīng)用。

Objective To explore the clinical efficacy of Ganhai Weikang Capsules combined with Esomeprazole Magnesium Enteric-coated Capsules in treatment of gastric ulcer. Methods A total of 124 patients with gastric ulcer admitted to Lianyungang Hospital Affiliated to Xuzhou Medical University from November 2020 to November 2022 were selected and divided into control group and treatment group according to random number table method, with 62 cases in each group. Patients in the control group were po administered with Esomeprazole Magnesium Enteric-coated Capsules, 20 mg/time, once daily. Patients in the treatment group were po administered with Ganhai Weikang Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy, Helicobacter pylori (Hp) eradication rate, and ulcer healing rate of two groups was evaluated. The typical performance score, the second version of the chronic disease quality of life scale (QLICD-PU V2.0) score, the ratio of serum pepsinogen I to pepsinogen II (PGR), gastrin-17 (G-17), and interleukin-6 (IL-6) levels were compared between the two groups. Results After treatment, the total effective rate of the treatment group was 96.77%, which was significantly higher than that of the control group (87.10%) (P < 0.05). After treatment, the scores of epigastric pain, distension, acid reflux, belching and their total scores were significantly decreased in both groups (P < 0.05). After treatment, the typical performance score of the treatment group decreased more significantly (P < 0.05). After treatment, the scores of common modules, specific modules and total scores of QLICD-PU V2.0 in both groups were significantly increased (P < 0.05). After treatment, QLICD-PU V2.0 score in the treatment group was higher than that in the control group (P < 0.05). Hp eradication rate and ulcer healing rate in treatment group were 91.94% and 75.81%, respectively, which were significantly higher than 79.03% and 58.06% in control group (P < 0.05). After treatment, serum levels of PGR, G-17 and IL-6 were significantly decreased in both groups (P < 0.05). After treatment, the serum levels of PGR, G-17 and IL-6 in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Ganhai Weikang Capsules combined with esomeprazole has good curative effect in treatment of gastric ulcer, and can effectively promote the reduction of typical manifestations, improvement of life quality, eradication of Hp and the healing of ulcer, and has a good regulatory effect on recovery of gastric mucosa function and the relief of inflammatory response, which is worthy of clinical application.

R975

連云港市第一人民醫(yī)院科研項(xiàng)目（SYSD2022-0163）